Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
RAUDIXIN vs ALDORIL 15
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Raudixin (reserpine) is an indole alkaloid that depletes catecholamines (norepinephrine, dopamine) and serotonin from central and peripheral neuronal storage granules by inhibiting vesicular monoamine transporter (VMAT). This leads to prolonged sympathetic blockade and reduced blood pressure.
Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.
Essential hypertension
Hypertension
Usual adult dose: 400–1600 mg orally per day in divided doses; maximum 2400 mg/day; for severe agitation: 50–100 mg intramuscularly every 4–6 hours.
1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.
Terminal elimination half-life 50-100 hours; clinical context: once-daily dosing achieves steady state in 1-2 weeks.
Terminal half-life: 12–17 hours; clinical context: steady-state achieved within 2–3 days; effect persists 12–24 hours
Extensively metabolized in the liver via hydrolysis to reserpic acid and methyl reserpate; also undergoes glucuronidation.
Methyldopa is metabolized in the liver via conjugation and O-methylation; active metabolites include methyldopamine and methylnorepinephrine. Hydrochlorothiazide is not significantly metabolized and is excreted unchanged in urine.
Primarily renal (80-90% as unchanged drug), minor biliary/fecal (10-20%).
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites
90-95% bound mainly to albumin and alpha-1 acid glycoprotein.
~90%, primarily to albumin
10-30 L/kg; large Vd indicates extensive tissue distribution, including adipose and brain.
2–4 L/kg; clinical meaning: extensive tissue distribution, concentrating in vascular smooth muscle
Oral: 35-50% due to first-pass metabolism; IM: 100%.
Oral: 50–60% (extensive first-pass metabolism)
No dose adjustment necessary for mild-to-moderate renal impairment (GFR ≥30 m L/min); severe renal impairment (GFR <30 m L/min): reduce dose by 25–50% and titrate cautiously.
GFR 30-50 m L/min: maximum 1 tablet twice daily. GFR <30 m L/min: avoid use.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 30–50%; Child-Pugh Class C: avoid use or use with extreme caution at reduced doses.
Child-Pugh A: caution, reduce dose. Child-Pugh B: avoid. Child-Pugh C: contraindicated.
Children 6–12 years: initial dose 0.2 mg/kg/day orally in divided doses, increase gradually up to 0.4–0.6 mg/kg/day; maximum 1.0 mg/kg/day. Not recommended for children <6 years.
Not recommended for pediatric use; safety in children under 12 years not established.
Elderly patients: start at 10–50% of adult dose (e.g., 100–200 mg/day orally), titrate slowly due to increased sensitivity and higher risk of sedation, anticholinergic effects, and orthostatic hypotension.
Start with 1 tablet once daily; monitor for hypotension and electrolyte imbalance. Reduce initial dose by 50%.
None.
None
May cause severe depression, especially in patients with a history of depression.,Use with caution in patients with peptic ulcer disease due to increased gastric acid secretion.,Risk of biliary colic in patients with gallstones.,Avoid use with MAOIs.,May cause withdrawal symptoms (e.g., severe hypertension) upon abrupt discontinuation.
Sedation, usually transient; may impair ability to drive or operate heavy machinery.,Positive Coombs test with hemolytic anemia (rare); monitor hematocrit and Coombs test.,Hepatotoxicity (hepatic necrosis) with fever, jaundice; discontinue if liver abnormalities occur.,Fluid and electrolyte imbalance (hypokalemia, hyponatremia, hypercalcemia) due to thiazide.,May precipitate gout in hyperuricemic patients.,May exacerbate systemic lupus erythematosus.
History of depression (especially suicidal ideation),Active peptic ulcer,Ulcerative colitis,Electroconvulsive therapy (within 7 days),Hypersensitivity to reserpine,Concomitant use with MAOIs
Active hepatic disease (e.g., acute hepatitis, cirrhosis),Prior methyldopa therapy associated with liver disorders,Hypersensitivity to methyldopa or hydrochlorothiazide,Anuria,Sulfonamide allergy (cross-sensitivity with thiazides)
Avoid tyramine-rich foods (aged cheese, cured meats, fermented products) due to risk of hypertensive crisis. Grapefruit juice may increase reserpine levels. Take with food to reduce gastric irritation.
Avoid high-sodium foods as they can reduce antihypertensive efficacy. Thiazides may cause hypokalemia; increase dietary potassium (bananas, orange juice) unless contraindicated. Alcohol may enhance orthostatic hypotension.
First trimester: Known human teratogen; may cause major congenital malformations (e.g., neural tube defects, cardiovascular anomalies). Second and third trimesters: Associated with neonatal withdrawal syndrome, respiratory depression, hypotonia, and feeding difficulties after prolonged exposure. Avoid use in pregnancy unless no safer alternative exists.
First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: Fetal and neonatal adverse effects including oligohydramnios, fetal renal dysfunction, skull ossification delay, and hypotension in the neonate. Avoid use after 20 weeks gestation unless no alternative.
Raudixin (methamphetamine hydrochloride) is contraindicated during breastfeeding due to high secretion into breast milk, potential for infant toxicity (irritability, poor feeding, seizures), and unknown M/P ratio. Discontinue nursing or drug.
Methyldopa and hydrochlorothiazide are excreted into human milk. M/P ratio for methyldopa is approximately 0.5-1.0; for hydrochlorothiazide, M/P ratio ~2.0. Methyldopa is considered compatible with breastfeeding. Hydrochlorothiazide may suppress lactation and cause neonatal electrolyte disturbances. Use with caution; monitor infant for signs of diuresis or electrolyte imbalance.
Pregnancy reduces methamphetamine clearance by up to 30% due to increased plasma volume and enhanced hepatic metabolism; however, no established dose adjustment in pregnancy. Monitor for toxicity and consider dose reduction if adverse effects occur. Avoid use due to teratogenicity.
Pharmacokinetic changes in pregnancy may include increased volume of distribution and enhanced renal clearance. No specific dose adjustment routine is recommended; dosing should be guided by clinical response. Methyldopa starting dose 250 mg twice daily, titrated to effect. Hydrochlorothiazide dose not typically adjusted, but caution due to potential volume depletion.
RAUDIXIN (reserpine) is a rauwolfia alkaloid that depletes catecholamines from central and peripheral nerve endings. It causes significant sedation, increased gastric acid secretion (caution in peptic ulcer disease), and nasal congestion. Use is limited due to risk of depression and extrapyramidal symptoms. Monitor for hypotension, especially orthostatic. Avoid concurrent use with MAOIs and tricyclic antidepressants.
Aldoril 15 (methyldopa 250mg + hydrochlorothiazide 15mg) is rarely used due to superior alternatives. Monitor for hepatotoxicity, hemolytic anemia, and lupus-like syndrome. Titrate slowly to avoid sedation. Contraindicated in active liver disease, pheochromocytoma, and anuria.
Do not stop taking abruptly; withdrawal can cause severe hypertension.,You may feel drowsy or dizzy; avoid driving until you know how the drug affects you.,Report any symptoms of depression, unusual dreams, or suicidal thoughts immediately.,Avoid alcohol and over-the-counter cold medications containing decongestants.,Rise slowly from sitting or lying to prevent falls due to blood pressure drop.
May cause drowsiness; avoid driving until tolerance develops.,Report unexplained fever, jaundice, or dark urine immediately.,Take at bedtime to minimize sedation.,Avoid sudden discontinuation; follow prescribed tapering schedule.,Use sun protection; thiazides increase photosensitivity.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about RAUDIXIN vs ALDORIL 15, answered by our medical review team.
RAUDIXIN is a Antihypertensive that works by Raudixin (reserpine) is an indole alkaloid that depletes catecholamines (norepinephrine, dopamine) and serotonin from central and peripheral neuronal storage granules by inhibiting vesicular monoamine transporter (VMAT). This leads to prolonged sympathetic blockade and reduced blood pressure.. ALDORIL 15 is a Antihypertensive Combination that works by Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between RAUDIXIN and ALDORIL 15 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of RAUDIXIN is: Usual adult dose: 400–1600 mg orally per day in divided doses; maximum 2400 mg/day; for severe agitation: 50–100 mg intramuscularly every 4–6 hours.. The standard adult dose of ALDORIL 15 is: 1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between RAUDIXIN and ALDORIL 15 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. RAUDIXIN is classified as Category C. First trimester: Known human teratogen; may cause major congenital malformations (e.g., neural tube defects, cardiovascular anomalies). Second and third trimesters: Associated with. ALDORIL 15 is classified as Category C. First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.